The combination of osimertinib (TKI) and GSI may be potentially beneficial for patients with EGFR-mutant NSCLC because NOTCH1 and Notch target genes are increased in osimertinib drug-tolerant persister (DTP) cells [42]. Here, NOTCH1 is linked to non-small cell lung carcinoma.